Pyridoxal phosphate

Drug Profile

Pyridoxal phosphate

Alternative Names: Avastrem; Cardoxal; MC-1; Pyridoxal 5'-phosphate; Tardoxal

Latest Information Update: 24 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medicure
  • Class Coenzymes; Ischaemic heart disorder therapies; Picolines; Small molecules
  • Mechanism of Action Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Drug-induced dyskinesia

Highest Development Phases

  • Phase II Drug-induced dyskinesia
  • Discontinued Lipid metabolism disorders; Myocardial infarction; Reperfusion injury; Stroke

Most Recent Events

  • 24 Jun 2015 Phase-II develoment for Drug-induced dyskinesia is ongoing in the US and Canada
  • 18 Aug 2014 Pyridoxal phosphate is available for licensing for Tardive dyskinesia as of 18 Aug 2014. http://www.medicure.com
  • 18 Aug 2014 Discontinued - Phase-I for Stroke in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top